Top applicants in US, EP, AU, and CA jurisdictions

 

 

Insight:

• ALLERGAN is the most prominent filer with 245 patent families. 9 patent families (US20190300583A1, US20190183987A1, US20190125844A1, US20210145955A1, US20210108187A1, US20200038492A1, US20210106660A1, US20200023044A1, US11260114B2) were filed by BONTI Inc. which has been acquired by the ALLERGAN in 2018 with an upfront payment of $195 million. Source
• 9 patent families (US20150196490A1, US10485855B2, US20120321579A1, US20190183785A1, US20120321571A1, US20120328549A1, US20160213757A1, US10758485B2, US8658391B2)  were filed by ANTERIOS, which has been later acquired by ALLERGAN in 2016 with upfront payment of $90 million. Source
• 4 Patent families (US20200383894A1, US20210330765A1, AU2020407634A1, AU2020404611A1) were jointly filed by the IPSEN and GALDERMA.
• The major focus of Allergan is BoNT for therapeutic uses. The company has filed 114 patents in this domain. Allergan is also involved in using BoNT in cosmetic and aesthetic purposes (7 patents), but not as much as therapeutics. The company has also filed 9 patents in Methods of Detection/Assays for the presence of BoNT in biological and chemical sample. One of such patents (US6585993B2) also holds a very high impact factor score of 361.

 

 

Significant applicant Vs BoNT formulation and/or BoNT application

Insight:

• ALLERGAN is the most prominent filer with 154 patent families. Out of these the company focused mainly on therapeutic uses of BoNT and BoNT formulations and filed for 114 patents focusing on it.
• Allergan also filed for 2 patents in the method of manufacture (US6967088B1, US8012716B2)
• A few high impact factor patents falling under these categories from the assignee Allergan are US6358926B2, US6368605B1, US6974578B1, US7468188B2, US7468189B2, US8420105B2, US8623999B2, US9066943B2, US9144692B2.
• Revance Therapeutics have filed 37 patents  out of which 2 patents are focused on the method of manufacturing BoNT formulations.
• Revance Therapeutics also possess 2 patents with a  high impact factor, US8404249B2 and US8962548B2.
• The top assignee Allergan has collaborated with a few notable players for development:
  • Health Protection Agency
  • Secretary Of State For Health
  • Regents Of University Of Colorado
  • Baylor College Of Medicine
  • FAC Systems

 

 

Significant applicant Vs Focus-BoNT peptide/toxin

 

Insight:

• Allergan is the most prominent filer with 35 patent families. Out of these the company focused mainly on BoNT as a product and filed for 114 patents focusing on it. Allergen has also collaborated with Baylor College of Medicine for publishing a patent on BoNT as a product.
• Allergan also filed for 3 patents in the method of purification of (US20090124790A1, US7452697B2, US9725705B2)
• MERZ have filed 24 patents  out of which 2 patents (US20150232828A1, US20170204391A1) are focused on the method of manufacturing BoNT as a compound/peptide.
• IPSEN has the highest number of patent filings in the domain of method of manufacturing BoNT as a compound/peptide (7 patents).